Sweden Women’s Health Market Size & Outlook, 2023-2030
Sweden women’s health market, 2018-2030 (US$M)
Related Markets
Sweden women’s health market highlights
- The Sweden women’s health market generated a revenue of USD 132.4 million in 2023 and is expected to reach USD 192.5 million by 2030.
- The Sweden market is expected to grow at a CAGR of 5.5% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 132.4 million |
| Market revenue in 2030 | USD 192.5 million |
| Growth rate | 5.5% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Sweden accounted for 0.3% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany women’s health market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 3,031.4 million by 2030.
Contraceptives was the largest segment with a revenue share of 33.08% in 2023. Horizon Databook has segmented the Sweden women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of targeted diseases is anticipated to create market opportunities for market players. In Sweden, the median age of menopause is 51 to 52 years and around 65,000 Swedish women reach menopause every year. Medical conditions associated with menopause such as hot flushes and night sweat increased the demand for medicinal products to manage these symptoms.
According to the European Journal of Contraception & Reproductive Health Care survey published in August 2022, around 62.4% of the total 1,016 Swedish women participants currently used contraception, and unmet need for contraception has increased to 17.2%.
Global players enter into strategic partnerships with local players to enhance their presence in the country, thereby gaining a high market share. Companies are involved in the introduction of novel therapeutic drugs for fertility, menopause, and other women’s health applications.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Sweden women’s health market size, by application, 2018-2030 (US$M)
Sweden Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
